Alida Biosciences, led by CEO Dr. Gudrun Stengel, develops epigenomic and epitranscriptomic research tools. Its core offerings include the EpiPlex RNA Library Prep Kit and the EpiScout Analysis Suite, which provide an integrated wet‑lab and bioinformatics solution for multiplexed detection and analysis of RNA modifications. The EpiPlex kit is positioned for profiling multiple RNA modifications in input‑limited clinical research samples, offering sensitivity and relative quantification on clinically relevant RNA inputs. EpiScout complements the kit by providing an intuitive platform to analyze and visualize complex epitranscriptomic data and support multiomic integration. The company says its products broaden the application of epitranscriptomics by enabling concurrent analysis of multiple RNA modifications with user‑friendly data interpretation. Alida raised $7.5M in a Series A and intends to use the proceeds to further enhance product development and bring the EpiPlex kit to market.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2024